Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 December 2023
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 June 2023
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2009
Guidance on the use of liquid-based cytology for cervical screening (TA69)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2003
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 October 2025
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after chemotherapy ID3753Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2026
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC